Enquiries to Ministry of Health 0800 855 066

## APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2383 December 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:	
Reg No:	First Names:	First Names:	
Name:	Surname:	Surname:	
Address:	DOB:	Address:	
	Address:		
Fax Number:  Posaconazole		Fax Number:	
Initial application Applications only from a haematologist or infectious Prerequisites(tick boxes where appropriate)  Patient has acute myeloid leukaem	s disease specialist. Approvals valid for 6 weeks.  nia and is to be treated with high dose remission indu  ansplant and has graft versus host disease and is on		
Renewal  Current approval Number (if known):  Applications only from a haematologist or infectiou  Prerequisites(tick boxes where appropriate)			
Patient has acute myeloid leukaemia and is to be treated with high dose remission induction, re-induction or consolidation therapy  Patient has received a stem cell transplant and has graft versus host disease and is on significant immunosuppression* and requires on going posaconazole treatment  Note: * Graft versus host disease (GVHD) on significant immunosuppression is defined as acute GVHD, grade II to IV, or extensive chronic GVHD, or if they were being treated with intensive immunosuppressive therapy consisting of either high-dose corticosteroids (1 mg or greater per kilogram of body weight per day for patients with acute GVHD or 0.8 mg or greater per kilogram every other day for patients with chronic GVHD), antithymocyte globulin, or a combination of two or more immunosuppressive agents or types of treatment.			
Initial application — Invasive fungal infection p Applications from any relevant practitioner. Approx Prerequisites(tick boxes where appropriate)  The patient is at risk of invasive fun	rophylaxis vals valid for 6 months.		
or paediatric haematologist or prescribing posaconazole is	by, or recommended by a haematologist, transplant poaediatric oncologist in accordance with a protocol or guideline that has becific settings where there is a greater than 10% risk	neen endorsed by the Health New Zealand - Te	

I confirm the above details are correct and that in signing this form I understand I may be audited.

Enquiries to Ministry of Health 0800 855 066

## APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 2 Form SA2383 December 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:	
Reg No:	First Names:	First Names:	
Name:	Surname:	Surname:	
Address:	DOB:	Address:	
	Address:		
Fax Number:		Fax Number:	
Posaconazole - continued			
Renewal — Invasive fungal infection prophylax	is		
Current approval Number (if known):			
Applications from any relevant practitioner. Approvals valid for 6 months.  Prerequisites(tick boxes where appropriate)			
The patient is at risk of invasive fur	ngal infection		
·	Posaconazole is prescribed by, or recommended by a haematologist, transplant physician, infectious disease specialist, paediatric haematologist or paediatric oncologist		
Prescribing posaconazole is	in accordance with a protocol or guideline that has becific settings where there is a greater than 10% risk	een endorsed by the Health New Zealand - Te of invasive fungal infection (IFI)	

I confirm the above details are correct and that in signing this form I understand I may be audited.